Multiple Myeloma Coverage from Every Angle

‘Good-Risk’ Myeloma: Study Finds Genomic Markers Prognostic of Prolonged Survival

By: Kayci Reyer
Posted: Sunday, November 1, 2020

According to research published in the Journal of Clinical Oncology, patients with multiple myeloma who had a genomic scar score of 5 or less plus chromosome 9 gain appeared to be more likely to experience prolonged survival than did patients with a genomic scar score above 5. Whole-genome sequencing was used to identify patients within what Nikhil C. Munshi, MD, of the Dana-Farber Cancer Institute, Boston, and colleagues referred to as a “good-risk” group.

“Interestingly, the superior outcome group identified here was independent of traditional clinical risk factors, such as ISS [International Staging System], response to treatment, and achievement of [minimal residual disease] negativity,” noted the authors.

The study included data on 183 patients newly diagnosed with multiple myeloma who had been treated with either lenalidomide/bortezomib/dexamethasone alone or with autologous stem cell transplantation. Using allele-specific copy-number alterations, a genomic scar score was determined for each patient. A total of 17% of patients were found to have low DNA damage, defined as a genomic scar score of 5 or less plus chromosome 9 gain.

The overall survival for this patient subgroup was 100% at 69 months. A lower mutational load, the substantial influence of age-related mutations, and frequent NRAS mutation were characteristic of this subgroup. When compared with other groups, this subgroup had a significantly reduced mutational load (P = .0002). Patients within the hyperdiploid myeloma subgroup had the lowest load, whereas those within the t(14;16) myeloma subgroup had the highest load (P = .004).

“Identifying these good-risk patients will affect clinical research and inform therapeutic algorithms in the future,” the author concluded.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.